Bessemer Group Inc Crinetics Pharmaceuticals, Inc. Transaction History
Bessemer Group Inc
- $61.3 Billion
- Q4 2024
A detailed history of Bessemer Group Inc transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Bessemer Group Inc holds 70 shares of CRNX stock, worth $2,409. This represents 0.0% of its overall portfolio holdings.
Number of Shares
70
Previous 235
70.21%
Holding current value
$2,409
Previous $12,000
66.67%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CRNX
# of Institutions
255Shares Held
89.5MCall Options Held
26.1KPut Options Held
11.8K-
Vanguard Group Inc Valley Forge, PA9.09MShares$313 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.95MShares$239 Million0.07% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$214 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$211 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$186 Million0.03% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.85B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...